BMS 986158

Ezobresib

It’s only fair to share… Ezobresib CAS 1800340-40-2 MF C30H33N5O2 MW 495.6 g/mol 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-olbromodomain and extra-terminal motif (BET) inhibitor,antineoplastic, BMS-986158, BMS 986158, Bristol Myers Squibb, antineoplastic, UNII-X8BW0MQ5PI 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Ezobresib is an investigational new drug that has been evaluated for the treatment of cancer. It inhibits Bromodomain and Extra-Terminal domain (BET) proteins, with potential antineoplastic activity.[1] Developed by Bristol Myers Squibb, this therapeutic agent has been …

It’s only fair to share… BMS 986158 MF C30H33N5O2, MW495.627 g/mol CAS 1800340-40-2 5H-Pyrido[3,2-b]indole-7-methanol, 3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-α,α-dimethyl-5-[(S)-phenyl(tetrahydro-2H-pyran-4-yl)methyl]- MOA：Bromodomain and extraterminal domain protein inhibitor Indication：Solid tumoursStatus： Phase II ：Bristol-Myers Squibb (Originator) Phase I/IISolid tumours Originator Bristol-Myers Squibb Class Antineoplastics; Small molecules Mechanism of Action Bromodomain and extraterminal domain protein inhibitors 01 Jun 2015 Phase-I/II clinical trials for Solid tumours (Late-stage disease, Metastatic disease) …